Optimizing the use of biological therapy in patients with inflammatory bowel disease

Gastroenterology Report

Volumn 3, Issue 1, 2015, Pages 63-68

  Moss, Alan C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biological therapy; Inflammatory bowel disease

Indexed keywords

EID: 85033597671     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou087     Document Type: Review

References (54)

1. Antunes O, Filippi J, Hebuterne X et al. Treatment algorithms in Crohn's: up, down or something else? Best Pract Res Clin Gastroenterol 2014;28:473-83.
2. Mandel MD, Miheller P, Mullner K et al. Have biologics changed the natural history of Crohn's disease? Dig Dis 2014; 32:351-9.
3. Lichtenstein GR, Feagan BG, Cohen RD et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. Am J Gastroenterol 2014;109:212-23.
4. Gisbert JP and Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
5. Vande Casteele N, Feagan BG, Gils A et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:378.
6. Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
7. Steenholdt C, Brynskov J, Thomsen OO et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti- TNF treatment: a randomised, controlled trial. Gut 2014;63: 919-27.
8. Sauerborn M, Brinks V, Jiskoot W et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010; 31:53-9.
9. Fasanmade AA, Adedokun OJ, Blank M et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from two phase III clinical trials. Clin Ther 2011;33:946-64.
10. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
11. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
12. O'Meara S, Nanda KS and Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1-6.
13. Nanda KS, Cheifetz AS and Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013;108:40-7; quiz 48.
14. Ben Horin S, Mazor Y, Yanai H et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012;35:714-22.
15. van de Casteele N, Cuypers L, Singh S et al. Antibodies to Infliximab can either be persistent or transient; a retrospective case-control study in IBD patients treated with Infliximab maintenance therapy. Gastroenterology 2012;143: 563.
16. Vande CN, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.
17. Coates MD, Lahoti M, Binion DG et al. Abdominal pain in ulcerative colitis. Inflamm Bowel Dis 2013;19:2207-14.
18. Farrokhyar F, Marshall JK, Easterbrook B et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38-46.
19. Gothe F, Beigel F, Rust C et al. Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings. J Crohns Colitis 2014;8:1072-8.
20. Nobrega AC, Ferreira BR, Oliveira GJ et al. Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease. BMC Gastroenterol 2012;12:175.
21. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
22. Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
23. Cornillie F, Hanauer S, Diamond RH et al. Can clinical, biological or pharmacological markers predict sustained response to infliximab? A retrospective analysis of ACCENT 1. Gut 2011; 60:A296.
24. Liu Y, Wu EQ, Bensimon AG et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012;29:620-34.
25. Beaugerie L and Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol 2012;18:3806-13.
26. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
27. Rostholder E, Ahmed A, Cheifetz AS et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012;35:562-7.
28. Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
29. Billioud V, Sandborn WJ and Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106:674-84.
30. Lichtenstein GR, Diamond RH, Wagner CL et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26.
31. Moss AC, Kim KJ, Fernandez-Becker N et al. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010;55:1413-20.
32. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
33. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.
34. Ben Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-47.
35. Ben-Bassat O, Romanova A, Lacono A et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn's disease. Gastroenterology 2013;144 (5 Suppl. 1):S775.
36. Cesarini M, Katsanos K, Papamichael K et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014;46:135-9.
37. Colombel JF, Sandborn WJ, Allez M et al. Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients with Crohn's Disease. Clin Gastroenterol Hepatol 2014;12:423-31.e1.
38. Vande Casteele N, Ballet V, Van Assche G et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012;61:321.
39. Velayos FS, Kahn JG, Sandborn WJ et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654-66.
40. vande Casteele N, Gils A, Ballet V et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol J 2013;1:A1-134.
41. Vaughn BP, Martinez-Vazquez M, Patwardhan VR et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996-2003.
42. Peyrin-Biroulet L, Reinisch W, Colombel JF et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63: 88-95.
43. Velayos F, Sheibani S, Lockton S et al. Prevalence of antibodies to adalimumab (ATA) and correlation between ATA and low serum drug concentration on CRP and clinical symptoms in a prospective sample of IBD patients. Gastroenterology 2013;144 (5 Suppl. 1):S490.
44. Reinisch W, Colombel JF, Sandborn WJ et al. Infliximab serum trough level and CRP change are associated with corticosteroid-free remission in Crohn's disease: a posthoc analysis of the sonic trial. Gut 2012;61 (Suppl. 2): A170.
45. Drastich P, Kozeluhova J, Jaresova M et al. Infliximab serum trough levels and deep remission in patients with IBD. Gastroenterology 2011;140 (5 Suppl. 1):S292.
46. Murthy S, Kevans D, Seow CH et al. Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis. Gastroenterology 2012;142 (5 Suppl. 1):S388.
47. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
48. Reinisch W, Feagan BG, Rutgeerts PJ et al. Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology 2012;142 (5 Suppl. 1):S114.
49. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
50. Steenholdt C, Bendtzen K, Brynskov J et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18.
51. Feagan BG, Singh S, Lockton S et al. Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology 2012;142 (5 Suppl. 1):S114.
52. Bortlik M, Duricova D, Malickova K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013;7:736-43.
53. Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40:620-8.
54. Imaeda H, Takahashi K, Fujimoto T et al. Accurate determination of serum adalimumab and anti-adalimumab antibodies levels during maintenance therapy for Crohn's disease. Gastroenterology 2013;144 (5 Suppl. 1):S431.